Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its unaudited financial statements for the three months ended March 31, 2025 are available online.

Rhea-AI Summary

Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its unaudited financial statements for the three months ended March 31, 2025 are available online. The documents can be accessed at the company's investor events and presentations page for review by shareholders and analysts.

Argus Oct 9 session

-46.67% close to close 10.0x rel. volume Open Argus

Details

News Market Reaction – EGRX

On Oct 9, the first trading day after this news, EGRX closed 46.67% below the previous close. That session’s volume was 10.0x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Oct 9 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at https://investor.eagleus.com/events-presentations.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.

Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Where can I find Eagle Pharmaceuticals (EGRX) unaudited Q1 2025 financial statements?

They are available at the company's investor site under Events & Presentations: https://investor.eagleus.com/events-presentations.

What period do the available Eagle Pharmaceuticals (EGRX) statements cover?

The documents cover the three months ended March 31, 2025.

Are the Q1 2025 financial statements for Eagle Pharmaceuticals (EGRX) audited?

No. The company specified these are unaudited financial statements.

Do the unaudited Q1 2025 statements from Eagle Pharmaceuticals (EGRX) include earnings or guidance?

The announcement only states availability of the unaudited statements; it does not specify earnings or guidance figures.

How should investors use Eagle Pharmaceuticals (EGRX) unaudited financial statements dated March 31, 2025?

Investors can review them for interim financial information but should note they are unaudited and may be subject to later adjustments.

Who can I contact for more information about Eagle Pharmaceuticals (EGRX) financial disclosures?

Use the contact information on the company's investor relations website or the investor events page where the documents are posted.